Clinical and Biological Database in Colon Cancer and Colic Tumors
NCT ID: NCT03976960
Last Updated: 2025-02-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
600 participants
INTERVENTIONAL
2018-09-19
2030-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Development of Clinical and Biological Database in Colorectal Cancer
NCT04186117
A Clinico-biological Database in Cachexia in Patients With Colon Cancer
NCT05257135
Circulating-free DNA Assessment as a Tool to Predict Colorectal Cancer in Subjects With a Positive Fecal Immunoassay.
NCT03981679
Circulating Tumor Cells and Neutrophils Count for Colorectal Metastatic Cancer
NCT05793775
Tumoral Circulating Cells and Colorectal Cancer Progression
NCT03256084
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Colorectal cancer is due to molecular and genetic damages involved in all tumorigenesis steps, transition from healthy tissue to adenoma and finally to invasive carcinoma stage. The investigators hope that a to better understand tumor invasion and metastatic scattering processes will allow therapeutic innovation and the emergence of new biomarkers.
However, the study of early tumorigenesis phases as well as advanced stages of the disease is currently limited due to a lack of tissue samples.
In this context, the Montpellier Cancer Institute (ICM) decided to initiate a biological collection dedicated to the tissular and blood samples of patients with colorectal cancer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Biological collection
For all the patients include in the study :
samples of blood samples collected before or after surgery but also samples in paraffin-embedded tissue sections.
In parallel to this biological collection, standardized clinical data will be entered into a database
Biological collection
The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biological collection
The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient operated for liver or lung or peritoneal carcinomatosis metastases originating from colon cancer
3. Patient operated for pre-neoplastic lesion (adenomatous polyp /villous adenoma polyp),
4. Patient with familial polyposis eligible for colectomy
5. Age \> 18 years
6. Signed informed consent
Exclusion Criteria
2. Patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons
3. Patient under guardianship
4. Minor patient
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut du Cancer de Montpellier - Val d'Aurelle
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ERIC ASSENAT, M.D
Role: STUDY_CHAIR
Institut régional du cancer de Montpellier
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHRU de Montpellier
Montpellier, Hérault, France
Institut Régional du cancer de Montpellier
Montpellier, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
ERIC ASSENAT, MD
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
National estimate of cancer incidence and mortality in France between 1980 and 2012.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BCB2014/01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.